Journal of Clinical Pharmacy and Therapeutics / 2024 / Article / Tab 5 / Research Article
The Neoadjuvant Administration of PD-1 Inhibitor plus Concurrent Chemoradiotherapy in Patients with Locally Advanced Esophageal Squamous-Cell Carcinoma Events Total, no. (%) Grade 1-2, no. (%) Grade 3-4, no. (%) Fatigue 12 (48.0) 12 (48.0) 0 (0.0) Nausea and vomiting 10 (40.0) 9 (36.0) 1 (4.0) Leukopenia 9 (36.0) 8 (32.0) 1 (4.0) Neutropenia 9 (36.0) 8 (32.0) 1 (4.0) Peripheral neuropathy 9 (36.0) 6 (24.0) 3 (12.0) Anemia 8 (32.0) 7 (28.0) 1 (4.0) Pruritus 8 (32.0) 7 (28.0) 1 (4.0) Hand-foot syndrome 8 (32.0) 8 (32.0) 0 (0.0) Elevated transaminase 7 (28.0) 7 (28.0) 0 (0.0) Diarrhea 5 (20.0) 5 (20.0) 0 (0.0) Thrombocytopenia 4 (16.0) 4 (16.0) 0 (0.0) Fever 4 (16.0) 4 (16.0) 0 (0.0) Anorexia 4 (16.0) 4 (16.0) 0 (0.0) Hypertension 4 (16.0) 4 (16.0) 0 (0.0) Elevated bilirubin 3 (12.0) 3 (12.0) 0 (0.0)